Affinity Asset Advisors »

Taysha Gene Therapies shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $9.8M 3.0M 3.27
2025-06-30 $462k 200k 2.31

More positions owned by Affinity Asset Advisors

Insmed Com Par $.01 (INSM)
Verona Pharma Sponsored Ads (VRNA)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Xenon Pharmaceuticals (XENE)
Madrigal Pharmaceuticals (MDGL)
Apogee Therapeutics (APGE)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)
Abivax Sa Sponsored Ads (ABVX)
Mineralys Therapeutics (MLYS)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Merus N V (MRUS)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Lexeo Therapeutics (LXEO)

View all positions for Affinity Asset Advisors

Top funds holding Taysha Gene Therapies

Rtw Investments
RA Capital Management
venBio Select Advisor
Morgan Stanley
BlackRock
FMR
Goldman Sachs Group
Vanguard Group
Siren
Octagon Capital Advisors
Point72 Asset Management
State Street Corporation
Vestal Point Capital
Deerfield Management Company
Polar Capital Holdings

View all funds holding Taysha Gene Therapies